Gotistobart

DB19100InvestigationalProtein Based Therapies

Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4
Curator reviewed
Code names: BNT316 · ONC-392

Resolves to

Compound

UNII4R46M31XXPCAS2226344-78-9

Targets

P16410CTLA4

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gotistobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account